A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

NCT00650793 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

473

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Extended Release OROS® Paliperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.